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T 
he  elucidation  of  the  separate  pathways  of  antigen 
presentation by MHC class  II molecules to CD4 + T 
cells and by MHC class I molecules to CD8 + T  cells has 
provided an understanding of how CD4 + helper responses 
can be directed at extracellular antigens while CD8 + cyto- 
toxic responses can be directed against intracellular antigens. 
Both dass I and class II molecules are made in the endoplasmic 
reticulum (ER). Class II molecules travel to a post-Golgi com- 
partment of the cell before their peptide-binding groove is 
charged with a tight-binding peptide. The peptides that load 
onto class II MHC molecules are produced in lysosomal com- 
partments and are derived from proteins that have been en- 
docytosed from the extracellular medium or that exist in the 
endosomal membrane. Newly synthesized MHC class I mol- 
ecules,  on the other hand, are loaded with peptides before 
they leave the ER. In this case, the bulk of the peptides come 
from cytosolic proteins that have been processed by protea- 
somes and transported into the ER via the specialized trans- 
porter associated with antigen processing (TAP) (1,  2). 
While immunologists have been aware for many years of 
the requirement for "specialized" or "professional" APCs to 
take up an extracellular antigen, degrade it, and present it to 
CD4 + T  cells  in association with MHC  class II,  for the 
most part, the requirement for such APC function in MHC 
class I-restricted responses has not been appreciated. There 
are several reasons for this lapse. MHC class I-associated peptide 
antigens mark the presenting cell for a lethal attack by CTLs. 
To avoid tissue destruction during an immune response, it 
is important that such marker peptides should bind almost 
irreversibly to the class I molecule and not be shed onto by- 
stander cells.  A  second block in our understanding of an- 
tigen presentation to CTL is the difficulty in imagining how 
an APC can introduce foreign proteins from an infected cell 
into its own class I pathway. This is because there is no estab- 
lished pathway by which a macrophage or dendritic cell can 
translocate extraceUular antigens into the cytosolic processing 
machinery that leads  to class I presentation.  This leads  to 
a major conceptual difficulty in understanding the initiaton 
of CTL responses to intracellular antigens. Thus, if only the 
pathogen-infected cell or the mutated tumor cell can present 
class  I-associated  antigen,  then  naive  CD8 +  T  cells  are 
limited to meeting antigens only at the peripheral site of in- 
fection or tumor growth. Since naive T cells do not extrava- 
sate into peripheral nonlymphoid tissues, and since many non- 
hematopoietic cells lack much of the costimulator function 
essential for T cell priming, it is clear that some mechanism 
must exist for presenting MHC class I-associated antigens 
on professional APC in the lymphoid organs.  Recently, a 
great deal of attention has focused on the priming of class 
I-restricted CTL in vivo and the need for professional APCs. 
The existence of such a presentation pathway is highlighted 
in the case of a colon carcinoma cell line expressing a model 
CTL antigen (3). After subcutaneous inoculation of the tumor 
cells, only host presentation to CD8 + T cells was shown to 
occur. Surprisingly, there was no direct contribution by the 
tumor cells to the presentation of antigen for T cell priming. 
Presently, there is general agreement that professional antigen 
presentation must occur for class I-restricted responses, and 
a number of different forms of professional presentation have 
been suggested, including (a) phagocytes may possess an ill- 
defined pathway to shunt protein from the phagosome into 
the cytosol, where it would enter the normal MHC class I-as- 
sociated pathway of antigen processing; (b) phagocytes may 
digest ingested material in lysosomes and regurgitate pep- 
tides to load onto surface MHC class I; and (c) heat shock 
proteins (HSPs), which may normally be part of a relay team 
carrying proteasome-derived peptides to MHC class I,  are 
released by dying infected or tumor cells, and these peptide 
carriers can access the cytosol of professional APCs. A paper 
in this issue by Arnold et al.  (4)  shows that a preparation 
of purified gp96 is able to prime a CD8 + T  cell response 
to a defined CTL epitope (4). This commentary will discuss 
each of these mechanisms. 
The realization that cell-associated antigens may be presented 
to the immune system by professional APCs grew out of an 
apparent contradiction between the rules of MHC restriction 
of CTL recognition and the older transplantation literature. 
The antigens presented by target cells expressing MHC  ^ al- 
leles are different and non-cross-reactive with the antigens 
presented by cells expressing MHC  B. Yet it was known from 
transplantation studies that MHC-mismatched grafts could 
prime host animals for second-set rejection of test grafts from 
MHC-matched donors if the priming and test grafts shared 
the same minor histocompatibility differences from the host 
(5, 6). Although it was unclear from such skin graft studies 
that class I-restricted CD8 + T cell priming was responsible 
for the rapid rejection, work in short-term CTL assays estab- 
lished that MHC-mismatched grafts could prime CD8 + T 
cells specific for minor histocompatibility antigens (7), H-Y 
antigen (8), and SV-40 T antigen (9). The priming effect was 
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response (10). This priming of CTL precursors in vivo, inde- 
pendent of the MHC type of the immunogenic cells, was 
referred to as "cross-priming" Since it would be of no advan- 
tage to have all endocytosed antigens presented to CD8 + T 
cells and to preserve the logic of the two pathways of antigen 
processing, I suggested that only particulate antigens, in the 
form of damaged cells,  would be processed by phagocytic 
APCs for class I presentation (11). 
In line with this suggestion, it was shown that model pro- 
tein antigens (such as hen OVA or Escherichia coli ~-galacto- 
sidase) could prime CTL responses in vivo much more effi- 
ciently as cell-associated rather than soluble antigens (12). 
In addition, lipid-encapsulated antigens (13), antigens on beads 
(14), or aggregated antigens (15-17) were effective in priming 
CD8 + T  cells  in vivo.  In  some cases,  it was  shown that 
compromising macrophage or dendritic cell function could 
abrogate the immunizing effect (18, 19). Rock and colleagues 
have presented evidence that a subset of phagocytic cells is 
capable of presenting peptides from exogenous bead-bound 
OVA in association with MHC class I molecules (20). Using 
peritoneal exudate cells from TAP-1 knockout mice, this group 
has shown a requirement for TAP function in this form of 
presentation in vitro, strongly implicating a phagosome to 
cytosol pathway. Using macrophage cell lines in this assay 
with various inhibitors further implicated the need for intact 
proteasome function and nascent class I molecules (20). 
In contrast to TAP-dependent presentation of particulate 
antigens to CD8 + T  cells stands  the description of a novel 
vacuolar class I processing pathway for exogenous phagocy- 
tosed antigens (21). According to this scheme, peptides pro- 
duced from phagocytosed material could load onto recycling 
class I molecules in vacuoles or may spew out of vacuoles 
to load onto the class I molecules on the surface of the same 
cell or a neighboring cell. Most of the data supporting this 
scenario have come from in vitro studies using recombinant 
E. coli or Salmonella expressing large amounts of a model an- 
tigen as a phagocytic substrate (21).  Other support for the 
notion of macrophages passing on antigen to dendritic cells 
has also come from in vivo studies with liposome-encapsulated 
OVA (19). It seems quite unlikely that this mechanism has 
any relevance to the presentation of typical cellular antigens 
to  CTL  precursors.  The  normal  processing  pathway for 
producing peptides that bind stably to MHC class I mole- 
cules begins in the cytosol with proteasome cleavages, and 
may continue in the ER when peptides are trimmed to the 
perfect size  for stabilizing class I molecules. It is unlikely 
(though not impossible) that vacuolar processing could mimic 
this.  The perfect "natural" peptides found in class I grooves 
can target cells for CTL recognition when present at picomolar 
levels, while longer or shorter versions of the peptide require 
103. to 106-fold higher concentrations to bind class I for rec- 
ognition by T cells (22). For antigenic protein substrates that 
exist in virus-infected or tumor cells at 1 to 0.01%  of the 
total cellular protein,  these levels of peptide would not be 
normally achieved by a vacuolar processing system. 
Another fascinating angle on how CTLs may meet an- 
tigens in vivo has emerged from studies that began analyzing 
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cellular immunity to chemically transformed tumors in in- 
bred mice. Animals could develop tumor-specific immunity 
by vaccination with irradiated tumor cells (23).  Painstaking 
efforts to identify the protective tumor antigen eventually 
focused attention on HSPs, including gp96, hsp90, and hsp70 
(24-27).  However, the sequence of the tumor-derived gp96 
did not differ from that of healthy tissues,  suggesting a pos- 
sible role of HSPs as peptide carriers. None of the tumor- 
specific antigenic peptides are known in these instances of im- 
munity to methylcholanthrene-induced  fibrosarcomas.  What 
Arnold et al. have done is to extend the findings using purified 
gp96 as an immunogen to include the CTL response to a 
B-galactosidase peptide (4). Thus, the lumenal gp96 purified 
from B-galactosidase-transfected  cells was shown to be capable 
of priming a CD8 + CTL response to/$-galactosidase and to 
unknown minor histocompatibility antigens. Remarkably, 
30 #g of soluble gp96,  presumably associated  with a vast 
complexity of cellular peptides, is able to prime the CD8 + 
response upon injection intraperitoneally into mice in the ab- 
sence of an adjuvant. Previous analysis of the cellular require- 
ments for the induction of tumor-specific immunity by HSP 
has shown that CD8 + cells are primed, and that previous 
depletion of phagocytic activity by carrageenan injection pre- 
vents the priming. Srivastava and colleagues have suggested 
that HSP carrying their chaperoned peptides are released by 
dying tumors or infected cells and bind to unknown receptors 
on the surface of macrophages (28).  They are then taken up 
into the cell to be routed to the macrophage nascent MHC 
class I molecules. The peptides are further processed during 
this translocation by the macrophage's own class I processing 
machinery. The work summarized above shows that HSPs 
purified from antigenic ceils have the capacity to prime class 
I-restricted CTL responses on the basis of the bound pep- 
tides.  There are no data available yet to explain whether in- 
terfering with this released HSP-macrophage receptor trans- 
location system would prevent the ability of APC to present 
antigen to CD8 + CTL in vivo. Nor are there any data about 
the in vitro processing of HSP-bound antigen for class I pre- 
sentation.  The  suggestion  that  HSP,  which may partici- 
pate in the normal transfer ofpeptides to MHC class I, could 
also be involved in efficient professional APC presentation 
to CTL,  however, preserves the logic of what type of an- 
tigens should be shunted into the class I pathway. 
The mononuclear cell type most frequently touted as both 
a professional APC and a phagocyte is the macrophage, while 
mature dendritic cells isolated in vitro have the reputation 
of being nonphagocytic. Since dendritic cells are so efficient 
in the presentation of antigen to T cells, however, they should 
not be ruled out for class I-restricted presentation (29). Under 
some circumstances, dendritic cells as interdigitating ceUs in 
central lymphoid organs and their precursors in the tissues, 
such as Langerhans cells in the skin, have been shown to be 
actively phagocytic. Fossum and Rolstad (30) showed that 
in situations where NK ceils are lysing allogeneic lympho- 
cytes, the interdigitating cells are very active in phagocytosing 
the donor ceils. Futhermore, bone marrow cultures stimu- 
lated with GM-CSF contain aggregates of dividing dendritic 
ceils that are actively phagocytic (31). In addition, Langerhans cells have also been shown to be phagocytic (32).  Thus, in 
the case of a local viral infection, for example, conditions may 
exist for Langerhans cells themselves to phagocytose infected 
cells, to shunt material into the class I processing pathway, 
and to migrate to the draining LN to present antigens to CTL. 
Address correspondence to Michael  J. Bevan, Howard Hughes Medical Institute and Department of Im- 
munology, University of Washington, I 604H HSB, Box 357370, Seattle, WA 98195-7370. 
Received for publication 9 May 1995 and in revised  form  15 June  1995. 
Re~l~ncos 
1.  Germain, R.N. 1994. MHC-dependent antigen processing and 
peptide presentation: providing ligands for T lymphocyte ac- 
tivation. Cell. 76:287-299. 
2.  Hill, A., and H. Ploegh. 1995. Getting the inside out:  the 
transporter associated  with antigen processing (TAP) and the 
presentation  of viral antigen.  Proc. Natl. Acad. Sci. USA. 
92:341-343. 
3.  Huang, A.Y.C., P. Golumbek, M. Ahmadzadeh, E. Jaffe, D. 
Pardoll, and H. Levitsky. 1994. Role of bone-marrow derived 
cells in presenting MHC class I-restricted tumor antigens. 
Science (FVash. DC). 264:961-965. 
4.  Arnold, D., S. Faath, H.-G. Rammensee, and H. Schild. 1995. 
Cross-priming of minor histocompatibility antigen  specific 
cytotoxic T cells  upon immunization with the heat-shock pro- 
rein gp96. f  Ex  F Med. 182:885-889. 
5.  Snell, G.D., N. Wheder, and M. Aaron. 1957. A new method 
of typing inbred strains of  mice for histocompatibility  antigens. 
Transplant. Bull. 4:18-21. 
6.  Gasser,  D.L., and W.K. Silvers. 1972. Genetics  and immunology 
of sex-linked antigens. Adv. Iramunol. 15:215-247. 
7.  Bevan,  MJ. 1976. Cross-priming for a secondary  cytotoxic re- 
sponse to minor H antigens with H-2 congenic cells which 
do not cross-react in the cytotoxic assay.  J. Exi~ Med. 143: 
1283-1288. 
8.  Gordon, R.B., L. Mathieson, L. Samelson, E. Boyse, and E. 
Simpson. 1976. The effect  of  allogeneic  presensitization  on H-Y 
graft survival and in vitro cell-mediated responses to H-Y an- 
tigen, f  Extx Med. 144:810-820. 
9.  Gooding, L.R., and C.B. Edwards. 1980. H-2 antigen require- 
ments  in the in vitro  induction  of SV40-specific cytotoxic 
T lymphocytes. J. Immunol. 124:1258-1262. 
10.  Bevan, MJ.  1976. Minor H  antigens introduced  on H-2 
different stimulating cells cross-react at the cytotoxic T cell 
level during in vivo priming. J. Immunol. 117:2233-2238. 
11.  Bevan,  M.J. 1987. Class discrimination in the world of  immu- 
nology. Nature (Land.). 325:192-194. 
12.  Carbone, F.R., and M.J. Bevan. 1990. Class I restricted pro- 
cessing and presentation of exogenous cell-associated  antigens 
in vivo. J. Ex  F Med. 171:377-387. 
13.  Zhou, F., B.T. Rouse, and L. Huang. 1992. Induction ofcyto- 
toxic T lymphocytes in vivo with protein entrapped in mem- 
branous vehicles,  f  Iramunol. 149:1599-1604. 
14.  Kovacsovics-Bankowski,  M., K. Clark, B. Benacerraf,  and K.L. 
Rock. 1993. Efficient major histocompatibility complex class 
I presentation  of  exogenous  antigen upon phagocytosis  by mac- 
rophages. Proc Natl. Acad. Sci. USA.  90:4942-4946. 
15.  Bachmann, M.F., T.M. Kundig, G. Freer, Y. Li, C.Y. Kang, 
D.H. Bishop, H. Hengartner, and lL.M. Zinkernagd.  1994. 
Induction of protective cytotoxic T ceils with viral proteins. 
Fur. f  Iramunol. 24:2228-2236. 
16.  Weidt, G., O. Unterm6hlen, J. Zerrhan, W. Deppert, and F. 
Lehmann-Grube. 1994. CD8 + T  lymphocyte-mediated an- 
tiviral immunity  in mice as a result of  injection of  recombinant 
viral proteins. J. Imraunol. 153:2554-2561. 
17.  Schirmbeck, K., W. B6hm, and J. Reimann. 1994. Injection 
of detergent-denatured ovalbumin primes murine class I-re- 
stricted cytotoxic  T cells  in vivo. Fur..]. Immunol. 24:2068-2072. 
18.  Debrick, J.E., P.A. Campbell, and U.D. Staerz. 1991. Macro- 
phages as accessory  cells for class I MHC-restricted immune 
responses, f  Immunol. 147:2846-2851. 
19.  Nair, S.,  A.M.J.  Buiting,  R.J.D.  Rouse, N.V. Rooijen, L. 
Huang, and B.T. Rouse. 1995. Role of macrophages and den- 
dritic ceUs in primary cytotoxic T lymphocyte responses. Int. 
Immunol. 7:679-688. 
20.  Kovacsovics-Bankowski,  M., and K. L. Rock. 1995. A phago- 
some-to-cytosol  pathway for exogenous antigens presented on 
MHC class I molecules. Science (Wash. DC). 267:243-246. 
21.  Pfeifer,  J.D., M.J. Wick, R.L. Roberts, K. Findlay, S.J. Nor- 
mark, and C.V. Harding. 1993. Phagocytic processing of bac- 
terial antigens for class I MHC presention to T ceils. Nature 
(Lond.). 361:359-362. 
22.  Rammensee, H.-G.,  K. Falk, and O. R6tzschke. 1993. Pep- 
tides naturally presented  by MHC class I molecules.  Annu. Rev. 
Iramunol. 11:213-244. 
23.  Srivistava,  P.K., and L.J. Old. 1988. Individually  distinct trans- 
plantation antigens of chemically  induced mouse tumors. Im- 
munol. Today 9:78-83. 
24.  UUrich, S.J, E.A. Robinson, L.W. Law, M. Willingham, and 
E. Appella. 1986. A mouse tumor-specific  transplantation an- 
tigen is a heat-shock  related protein. Proc Natl. Acad. Sci. USA. 
83:3121-3125. 
25.  Udono, H., and P.K. Srivastava. 1993. Heat-Shock protein-70 
associated peptides elicit specific  cancer immunity.J. Ex  F Med. 
178:1391-1396. 
26.  Udono, H., and P.K. Srivastava. 1994. Comparison of tumor- 
specific immunogenicities of stress-induced proteins Gp96, 
Hsp90, and HspT0. f  Iramunol. 152:5398-5403. 
27.  Udono, H., D.L.l.evey,  and P.K. Srivastava. 1994. Cellular 
requirements for tumor-specific  immunity elicited  by heat-shock 
proteins. Tumor rejection antigen-Gp96 primes CD8 ~ T cells 
in vivo. Proc. Natl. Acad. Sci. USA.  91:3077-3081. 
28.  Srivastava,  P.K., H. Udono, N.E. Blachere,  and Z.H. Li. 1994. 
Heat-Shock proteins transfer  peptides  during antigen processing 
and CTL priming. Immunogenetics. 39:93-98. 
29.  Steinman, R.M. 1991. The dendritic cell and its role in im- 
munogenicity. Annu. Rev. Imraunol. 9:271-296. 
30.  Fossum,  S., and B. Rolstad. 1986. The roles of interdigitating 
cells and natural killer cells in the rapid rejection of allogeneic 
lymphocytes. Eur. J. Immunol. 16:440-450. 
31.  Inaba, K., M. Inaba, M. Naito, and R. M. Steinman. 1993. 
Dendritic cell progenitors phagocytose particulates, including 
Bacillus Calmette-Gu6rin organisms, and sensitize mice to 
mycobacterial antigens in vivo.  J. Ext~ Med. 178:479-488. 
32.  Reis  e Sousa, C., P.E. Stahl, andJ.M. Austyn. 1993. Phagocy- 
tosis of antigens by Langerhans cells in vitro. J. Ex  F Med. 
178:509-519. 